← Back to Search

Intermittent Fasting for Chronic Lymphocytic Leukemia

N/A
Waitlist Available
Led By Nicol Macpherson, MD, PhD, FRCPC
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up within 3 months pre-intervention, monthly during intervention, 1 month post-intervention
Awards & highlights

Summary

This trial will compare 16/8 and 5:2 intermittent fasting methods in patients w/ chronic lymphocytic leukemia to find which is preferred and has greater effects on cancer cells, metabolism, inflammation, and gut microbiome.

Who is the study for?
This trial is for people under 85 with chronic B-cell leukemia or lymphoma, who have certain blood and health status markers. They must have completed a prior fasting study and not be on treatments that conflict with fasting.Check my eligibility
What is being tested?
The study compares two intermittent fasting methods (16/8 and 5:2) in their effects on cancer cells, metabolism, inflammation, and gut microbiome in patients who've done the 16/8 method before.See study design
What are the potential side effects?
Intermittent fasting may cause fatigue, hunger, irritability, headaches during fast periods. Long-term effects are still being studied but could include nutrient deficiencies if not managed properly.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time frame: within 3 months pre-intervention, monthly during intervention, 1 month post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and time frame: within 3 months pre-intervention, monthly during intervention, 1 month post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in autophagy status
Change in inflammation
Change in lymphocyte count [ Time Frame: Within 3 months pre-intervention, monthly during intervention, 1 month post-intervention ]
+2 more
Secondary outcome measures
Change in gut microbiome (optional)

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 5:2 MethodExperimental Treatment1 Intervention
Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week ("normal days") and limiting total calorie intake to 800kcals per day ("fasting days") for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference.
Group II: 16/8 MethodActive Control1 Intervention
Participants will have already followed the 16/8 Method (an intermittent fasting regimen) for a minimum of six days per week for a 90 day duration. This entailed limiting the eating hours to an 8-hour window, then fasting for the remaining 16 hours per day, with the last time of intake being 8pm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
5:2 Method (intermittent fasting regimen)
2023
N/A
~10

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Chronic Lymphocytic Leukemia (CLL) include Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, monoclonal antibodies, purine analogs, and alkylating agents. BTK inhibitors, such as ibrutinib, block the BTK enzyme, which is crucial for B-cell receptor signaling, thereby inhibiting the growth and survival of CLL cells. BCL2 inhibitors, like venetoclax, promote apoptosis in CLL cells by targeting the BCL2 protein that prevents cell death. Monoclonal antibodies, such as rituximab, bind to specific antigens on CLL cells, marking them for destruction by the immune system. Purine analogs and alkylating agents, such as fludarabine and cyclophosphamide, interfere with DNA replication and repair, leading to cell death. These treatments are significant for CLL patients as they target the disease at multiple levels, improving survival rates and quality of life. Additionally, understanding their mechanisms can help in exploring complementary therapies like intermittent fasting, which may modulate metabolic and immunological pathways to enhance treatment efficacy.
Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies.Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,481 Total Patients Enrolled
University of VictoriaOTHER
57 Previous Clinical Trials
11,632 Total Patients Enrolled
BC Cancer FoundationOTHER
17 Previous Clinical Trials
8,353 Total Patients Enrolled

Media Library

5:2 Method (intermittent fasting regimen) Clinical Trial Eligibility Overview. Trial Name: NCT05708326 — N/A
Chronic Lymphocytic Leukemia Research Study Groups: 16/8 Method, 5:2 Method
Chronic Lymphocytic Leukemia Clinical Trial 2023: 5:2 Method (intermittent fasting regimen) Highlights & Side Effects. Trial Name: NCT05708326 — N/A
5:2 Method (intermittent fasting regimen) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05708326 — N/A
~3 spots leftby Jul 2025